Interaction Studies of Ciprofloxacin and Metformin in Type 11 Diabetic Patients

Main Article Content

Musa Abdullahi Garba
Haruna Danbaba Anas
Bakare-Odunola Abduljalal
Thaibet Moji
Garba Magaji


Metformin is mostly prescribed with ciprofloxacin in the treatment of diabetic disease with infections. However, the effect of this drug on the pharmacokinetic profile of metformin is yet to be established. The study was aimed at investigating the influence of ciprofloxacin when co-administered with metformin to freshly diagnosed patients. It is a one-way single dose cross-over study in two phases. The subjects acted as their control, and each phase was preceded by an overnight fast. In phase one, metformin was administered to all the diabetic patients, while in phase two metformin was co-administered with 500 mg ciprofloxacin. Plasma glucose levels were determined using the standard glucose oxidase method. Blood samples were collected at 0, 0.5, 1.5, 3.0, 4.0, 6.0, 8.0 and 24 h post-drug administration and stored at – 4 ?C before analysis. Plasma was obtained from the blood and the drug was extracted from the plasma using three times its volume of acetonitrile. The samples were analyzed for metformin using a reversed phase. The Ka, Cmx t1/2 and AUC of metformin when administered alone were 0.46 ±0.04 h-1, 1.14 ±0.52 ?g/ml, AUC 4.39 h?g/ml/h respectively, When co-admistered with ciprofloxacin Ka increased to 0.68 ± 0.04 h-1, Cmax to 1.43 ± 0.35 ?g/ml; while AUC and t1/2? increased to 5.72 ± 0.02 ?gh/ml and 6.8 ± 0.02 h, respectively. These increments were found to be significant (p < 0.05).Our findings showed that metformin may be co-administered with ciprofloxacin to Type 2 diabetic Patients with cautions to avoid the possible risk of toxicity or therapeutic failure.


Download data is not yet available.

Article Details

How to Cite
Garba, M. A., Anas, H. D., Abduljalal, B.-O., Moji , T., & Magaji, G. (2020). Interaction Studies of Ciprofloxacin and Metformin in Type 11 Diabetic Patients. Nigerian Journal of Pharmaceutical and Applied Science Research, 9(1), 41–45. Retrieved from
Author Biographies

Musa Abdullahi Garba

Department of Pharmaceutical and Medicinal Chemistry, Kaduna State University, Kaduna, Nigeria

Haruna Danbaba Anas

Department of Pharmaceutical and Medicinal Chemistry, Kaduna State University, Kaduna, Nigeria

Bakare-Odunola Abduljalal

Department of Pharmaceutical and Medicinal Chemistry, Kaduna State University, Kaduna, Nigeria

Thaibet Moji

Department of Pharmaceutical and Medicinal Chemistry, University of Ilorin, Kwara State, Nigeria

Garba Magaji

Department of Pharmaceutical and Medicinal Chemistry, Ahmadu Bello University, Zaria, Nigeria


ADA (American Diabetes Association) (2013). Nutritional recommendations and principles for an individual with diabetes Mellilus. Diabetes care .10:126 – 132.

Bailey CJ 2012. Biguanides and NIDDM. Diabetes Care., 15(6): 755-772.

Bakare-Odunola MT, Garba M., Enemali SI., Okeniyi SO. and Gebi J (2001).The influence of ampicillin/cloxacillin on the pharmacokinetics of chlorpropamide in Type 2 diabetic patients.West African Journal of Parmacology. Drug Research 17: (1and 2) 74-76.

Bhavesh D, Chetan,G , Bhat KM. and Shivprakash, “Estimation and pharmacokinetics of Metformin in human volunteers”Indian Journal of Pharmarceutial Education Research, 2007;41(2):135-139.

Bonfigli AR, Manfrini S, Gregorio F, Testa R, Testa I, Sio G and Coppa G.( 2013). Determination of plasma Metformin by new cation exchange HPLC technique. 21(3):330-334.

Charles BG , Precechagoom, Y, Lee TC ,Sheer PA , Flennady VJ and Debuse, N (2009). Population pharmacokinetics of intravenous amoxicillin in very low birth weight infants. Journal of Pharmaceutical Sciences. 86(22):1288-12292.

Cheng CL and Chou CH. (2001). Determination of Metformin in human plasma by High performance liquid chromatography with spectrophotometric determination. J. Chromatogr B. Biomed Sci. Appl., 762(1): 51-58.

Denno KM and Saddle TW (2009). Effects of biguanidine class of oral hypoglycemic agents on mouse embryogenesis. Teratology., 49(4): 260-266.

Garba MA, Bakare-Odunola MT, Garba M,.Haruna A and Bako R (2018). Effects of metronidazole and amoxicillin on the pharmacokinetics of metformin in type ii diabetic patients. FUW Trends in Science & Technology Journal, e-ISSN: 24085162; p-ISSN: 20485170; April, 2018: Vol. 3 No. 1 pp. 309 – 313

Hermann LS (2010). Clinical pharmacology of biguanides. In: Kulhmann I, Plus W editor. Hand Book of Experimental Pharmacology.Hiedelberg: Springer Veelog, pp. 374 - 407.

Hermann LS (2013). Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab., 5(3): 233-45.

Hills S (1987). Penicillin Antibiotics. In: Antibiotics in Clinical use. Oxford University Press, London. pp 2-4.

Joel IU, Atul D, Diane TL (2012). PK Function on Microsoft excel. Department of Pharmacokinetics and drug Metabolism. Allergen, Irvine, CA 92606. USA

Marathe PH, Arnold ME, Meeker J, Greene DS, Barbhaiya RH (2000). Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. Journal of Clinical Pharmacology 40: 1494-1502.

Melmed S, Polonsky KS, Larsen PR and Kronenberg, H.M. (2012). Williams Textbook of Endocrinology, 12th Edn. Philadelphia: Elsevier/Saunders. pp. 1371–1435.

PattanaSripalakit A.B, PenpornNeamhom .B, AurasornSaraphnhotiwitthaya C ( 2006). High performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to pharmacokinetic study Journal of Chromatography B; 843: 164-169.

Paxton WJ (1989). Drug absorption and distribution. In: Pharmacokinetics in clinical practice The New Zealand Medical Journal. 694: 304-306.

Pentikainen PJ, Neuvonen PJ and Pentilla A (2010). Pharmacokinetics of Metformin after Intravenous and oral administration to man. Eur. J. Clin. Pharmacol., 16(3): 683- 693.

Ptalsky KM (1980).Disease-induced changes in the plasma binding of basic drugs. Clinpharmacokin.5; 246-262.

Rowland M and Tozer TN (1995). “Clinical pharmacokinetics Cocepts and applications”3rd Edition, Lea & Febiger ,Philadelphia, London.

Tucker GT, Casey C, Philips PJ, Con nor H, Ward JD, Wooda HF 2010. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. British Journal of. Clinical . Pharmacology. 12(2): 235-246.

Sambo GI, Bakare-Odunola MT, Aminu M, Ibrahim AY, Magaji G and Adzu B (2019). Effect of amodiaquine on the pharmacokinetics of glicliazide in diabetic subjects.African journal of pharmacy and pharmacology.13 (11) 139-145.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with Metformin on complications in overweight patients with type 2 Diabetes (UKPDS 34) Lancet, 1998;352:854–65.

Zarghi A, Foroustan SM, Shafaati A and Khoddam A (2003). Rapid determination of Metformin in human plasma using ion-pair HPLC. J. Pharm Biomed Anal., 31(1): 197-200.

Zhang M, Moore GA, Lever M, Gardiner SJ, Kirkpatric CM and Begg EJ( 2002). Rapid and simple High-performance liquid chromatography assay for the determination of Metformin in human plasma and breast milk. J. Chromatogr B Analyt Technol Biomed Life Sci., 766(1): 175-179.